Journal Article

FZJ-2023-00157

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study

Altomare, D. (Corresponding author) ; Collij, L. ; Caprioglio, C. ; Scheltens, P. ; van Berckel, B. N. M. ; Alves, I. L. ; Berkhof, J. ; de Gier, Y. ; Garibotto, V. ; Moro, C. ; Poitrine, L. ; Delrieu, J. ; Payoux, P. ; Saint-Aubert, L. ; Molinuevo, J. L. ; Grau-Rivera, O. ; Gispert, J.-D. ; Minguillón, C. ; Fauria, K. ; Sanchez, M. F. ; Rădoi, A. ; Drzezga, A.FZJ* ; Jessen, F. ; Escher, C. ; Zeyen, P. ; Nordberg, A. ; Savitcheva, I. ; Jelic, V. ; Walker, Z. ; Lee, H.-Y. ; Lee, L. ; Demonet, J.-F. ; Plaza Wuthrich, S. ; Gismondi, R. ; Farrar, G. ; Barkhof, F. ; Stephens, A. W. ; Frisoni, G. B. ; Consortium, A.

2023
Wiley Hoboken, NJ

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/34203  doi:10.1002/alz.12696

Abstract: Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort.Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.Keywords: Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline.

---

Contributing Institute(s):

1. Molekulare Organisation des Gehirns (INM-2)

Research Program(s):

1. 5252 - Brain Dysfunction and Plasticity (POF4-525) (POF4-525)
2. 5253 - Neuroimaging (POF4-525) (POF4-525)

Appears in the scientific report 2023

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---